Aktis Oncology, Inc. (AKTS) vs MoonLake Immunotherapeutics (MLTX)
A side-by-side comparison of Aktis Oncology, Inc. and MoonLake Immunotherapeutics across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AKTS
Aktis Oncology, Inc.
$18.10HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
MLTX
MoonLake Immunotherapeutics
$11.16HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
Total return — AKTS vs MLTX
growth of $100 · dividends reinvested · last 1yAKTS -17.3% (-17.3%/yr)MLTX -20.6% (-20.6%/yr)AKTS compounded faster over this window
AKTS MLTX
AKTS vs MLTX: by the numbers
- •AKTS is the larger company ($967M vs $939M market cap).
- •Both run net losses; MLTX's is the smaller (0.00% vs -727.04% net margin).
Metrics side by side
Valuation
| Metric | AKTS | MLTX |
|---|---|---|
| P/S ratio | 96.09 | N/A |
| P/B ratio | 1.99 | 2.19 |
Profitability
| Metric | AKTS | MLTX |
|---|---|---|
| Gross margin | 100.00% | 0.00% |
| Operating margin | -1149.52% | 0.00% |
| Net margin | -727.04% | 0.00% |
| ROE | -15.09% | -61.58% |
| ROIC | -16.54% | -50.77% |
Growth (annualized)
| Metric | AKTS | MLTX |
|---|---|---|
| Total return CAGR (5Y) | N/A | 2.81% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.